 |
12 Diseases |  |
0 Trials |
|
0 Trials |  |
31 News |  |
- | Journal: Recent development of piperazine and piperidine derivatives as antipsychotic agents. (Pubmed Central) - Jun 22, 2021
In the present review, we include the studies related to the effect of different substituents on piperidine/piperazine derivatives and their anti-psychotic activity. Various series of synthesized compounds by different researchers with piperidine/piperazine nucleus have been reviewed and diagrammatically represented in the form of SAR (structure activity relationships) which will help to the scientists for the development of potential lead compounds.
- | nelonicline (ABT-126) / AbbVie
Clinical, P2b data, Journal: Efficacy and Safety of the α7-Nicotinic Acetylcholine Receptor Agonist ABT-126 in the Treatment of Cognitive Impairment Associated With Schizophrenia: Results From a Phase 2b Randomized Controlled Study in Smokers. (Pubmed Central) - Aug 30, 2019
P2
A trend for improvement in negative symptoms was observed with the high dose. The safety profile of ABT-126 was similar to placebo.
- | nelonicline (ABT-126) / AbbVie
Trial termination, Trial primary completion date: Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Extension Study for Subjects Completing Study M10-855 (NCT01655680) (clinicaltrials.gov) - Oct 28, 2014
P2, N=268, Terminated, Sponsor: AbbVie
The safety profile of ABT-126 was similar to placebo. Active, not recruiting --> Terminated | Trial primary completion date: Aug 2015 --> Oct 2014; Study endpoint in preceding base study M10-855 not met.
- ||| nelonicline (ABT-126) / AbbVie
Enrollment closed, Trial primary completion date: Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Extension Study for Subjects Completing Study M10-855 (NCT01655680) (clinicaltrials.gov) - Sep 22, 2014
P2, N=271, Active, not recruiting, Sponsor: AbbVie
Active, not recruiting --> Terminated | Trial primary completion date: Aug 2015 --> Oct 2014; Study endpoint in preceding base study M10-855 not met. Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Feb 2015 --> Aug 2015
- |||| nelonicline (ABT-126) / AbbVie
Trial completion: A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia (clinicaltrials.gov) - Aug 15, 2014
P2, N=432, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Feb 2015 --> Aug 2015 Active, not recruiting --> Completed
- |||| nelonicline (ABT-126) / AbbVie
Trial completion: A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia (clinicaltrials.gov) - Mar 26, 2014
P2, N=156, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- nelonicline (ABT-126) / AbbVie
Trial termination: Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease (clinicaltrials.gov) - Mar 20, 2014
P2, N=343, Terminated, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Active, not recruiting --> Terminated; Data obtained from the M11-428 study is not critical to the continued evaluation of ABT-126.
- | nelonicline (ABT-126) / AbbVie
Trial termination: This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease (clinicaltrials.gov) - Mar 20, 2014
P2, N=349, Terminated, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Terminated; Data obtained from the M11-428 study is not critical to the continued evaluation of ABT-126. Active, not recruiting --> Terminated; Data obtained from the M11-427 study is not critical to the continued evaluation of ABT-126.
- ||| nelonicline (ABT-126) / AbbVie
Enrollment closed: A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia (clinicaltrials.gov) - Jan 6, 2014
P2, N=430, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Terminated; Data obtained from the M11-427 study is not critical to the continued evaluation of ABT-126. Recruiting --> Active, not recruiting
- |||| nelonicline (ABT-126) / AbbVie
Trial completion: Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease (clinicaltrials.gov) - Nov 18, 2013
P2, N=438, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||| nelonicline (ABT-126) / AbbVie
Trial completion: Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors (clinicaltrials.gov) - Nov 3, 2013
P2, N=434, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| nelonicline (ABT-126) / AbbVie
New P2 trial: Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Extension Study for Subjects Completing Study M10-855 (NCT01655680) (clinicaltrials.gov) - Apr 16, 2013
P2, N=271, Enrolling by invitation, Sponsor: AbbVie
- |||| nelonicline (ABT-126) / AbbVie
Enrollment open: Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Extension Study for Subjects Completing Study M10-855 (NCT01655680) (clinicaltrials.gov) - Apr 15, 2013
P2, N=271, Enrolling by invitation, Sponsor: AbbVie
Active, not recruiting --> Completed Not yet recruiting --> Enrolling by invitation
- nelonicline (ABT-126) / AbbVie
New P2 trial: Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease (clinicaltrials.gov) - Sep 19, 2012
P2, N=343, Terminated, Sponsor: AbbVie (prior sponsor, Abbott)
- ||||| nelonicline (ABT-126) / AbbVie
New P2 trial: A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia (clinicaltrials.gov) - Sep 3, 2012
P2, N=156, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
- | nelonicline (ABT-126) / AbbVie
New P2 trial: This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease (clinicaltrials.gov) - Aug 29, 2012
P2, N=349, Terminated, Sponsor: AbbVie (prior sponsor, Abbott)
- ||||| nelonicline (ABT-126) / AbbVie
New P2 trial: A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia (clinicaltrials.gov) - Jul 31, 2012
P2, N=430, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
- | nelonicline (ABT-126) / AbbVie
Trial completion: A Phase 1 Study of the Safety, Tolerability and Pharmacokinetics of ABT-126 in Subjects With Alzheimer's Disease (clinicaltrials.gov) - Apr 30, 2012
P1, N=20, Completed, Sponsor: Abbott
Not yet recruiting --> Enrolling by invitation Recruiting --> Completed
- ||||| nelonicline (ABT-126) / AbbVie
New P2 trial: Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors (clinicaltrials.gov) - Mar 7, 2012
P2, N=434, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
- ||||| nelonicline (ABT-126) / AbbVie
New P2 trial: Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease (clinicaltrials.gov) - Feb 5, 2012
P2, N=438, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
- | nelonicline (ABT-126) / AbbVie
New P1 trial: A Phase 1 Study of the Safety, Tolerability and Pharmacokinetics of ABT-126 in Subjects With Alzheimer's Disease (clinicaltrials.gov) - Nov 20, 2011
P1, N=20, Completed, Sponsor: Abbott
- |||| nelonicline (ABT-126) / AbbVie
Trial completion: Safety and Efficacy Study for Cognitive Deficits in Adult Subjects With Schizophrenia (clinicaltrials.gov) - Sep 18, 2011
P2, N=207, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Completed Active, not recruiting --> Completed